Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study

Gynecologic Oncology

Volumn 99, Issue 3 SUPPL., 2005, Pages

  Sarkar, Asis K ^a   Tortolero Luna, Guillermo ^a,b   Follen, Michele ^a,c   Sastry, K Jagannadha ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cell mediated immunity; CIN; Cytokines; HPV; Peptides

Indexed keywords

ARGINYLALANYLHISTIDYLTYROSYLASPARAGYLISOLEUCYLVALYLTHREONYLPHENYLALANNE; ARGINYLLEUCYLCYSTEINYLVALYLGLUTAMYLSERYLTHREONYLHISTIDYLVALINE; ASPARTYLLEUCYLGLUTAMYLPROLYLGLUTAMINYLTHREONYLTHREONYLASPARTYLLEUCINE; CYSTEINYLVALYLTYROSYLCYSTEINYLLYSYLGLUTAMYLGLUTAMYLLEUCYLLEUCYLARGININE; CYTOKINE; GLUTAMINYLLEUCYLGLUTAMYLTHREONYLTHREONYLISOLEUCYLHISTIDYLASPARTYLISOLEUCYL ISOLEUCINE; GLUTAMYLALANYLGLUTAMINYLPROLYLASPARTYLARGINYLALANYLHISTIDYLTYROSYL ASPARAGYLISOLEUCYLVALYLTHREONYLPHENYLALANYLCYSTEINYLCYEINYLLYSYLCYSTEINYL ASPARTIC ACID; GLUTAMYLLEUCYLLEUCYLARGINYLARGINYLGLUTAMINYLVALYLTYROSYLASPARTYL PHENYLALANYLALANYLPHENYLALANYLARGINYLASPARTYLLEUCINE; GLYCYLTHREONYLLEUCYLGLYCYLISOLEUCYLVALYLCYSTEINYLPROLYLISOLEUCYLCYSTEINE; LEUCYLLEUCYLMETHIONYLGLYCYLTHREONYLLEUCYLGLYCYLISOLEUCYLVALINE; LYSYLLEUCYLPROLYLGLUTAMYLLEUCYLCYSTEINYLTHREONYLGLUTAMINYLLEUCINE; METHIONYLLEUCYLASPARTYLLEUCYLGLUTAMYLPROLYLGLUTAMINYLTHREONYLTHREONINE; PROLYLLEUCYLCYSTEINYLASPARTYLLEUCYLLEUCYLISOLEUCYLARGINYLCYSTEINYL ISOLEUCINE; PROLYLTYROSYLALANYLVALYLCYSTEINYLASPARTYLLYSYLCYSTEINYLLEUCINE; PROTEIN E6; PROTEIN E7; THREONYLLEUCYLHISTIDYLGLUTAMINYLTYROSYLMETHIONYLLEUCYLGLUTAMINYLLEUCYL GLUTAMINE; UNCLASSIFIED DRUG; VALYLTYROSYLASPARTYLPHENYLALANYLALANYLPHENYLALANYLARGINYLASPARTYLLEUCYL CYSTEINE;

ADOLESCENT; ADULT; COLPOSCOPY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; TH1 CELL; UTERINE CERVIX CARCINOMA IN SITU;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 28844450322     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.099     Document Type: Conference Paper

References (68)

1. D.M. Parkin, P. Pisani, and J. Ferlay Estimates of the worldwide incidence of 25 major cancers in 1990 Int. J. Cancer 84 1999 827 841
2. WHO website (http://www.who.int/ ) incidence and mortality of cancers
3. L.A. Brinton Epidemiology of cervical cancer-Overview N. Munoz F.X. Bosch K.V. Shah A. Meheus The epidemiology of cervical cancer and human papillomavirus IARC Sci. Publ. vol. 119 1992 Oxford Univ. Press Lyon 3 23
4. N. Munoz, F.X. Bosch, S. de Sanjose, L. Tafur, I. Izarzugaza, and M. Gili The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Spain and Colombia Int. J. Cancer 52 1992 743 749
5. A.T. Lorincz, R. Reid, A.B. Jenson, M.D. Greenberg, W. Lancaster, and R.J. Kurman Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types Obstet. Gynecol. 79 1992 328 337
6. F.X. Bosch, M.M. Manos, N. Munoz, M. Sherman, A.M. Jansen, and J. Peto Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group J. Natl. Cancer Inst. 87 1995 796 802
7. M.H. Schiffman, H.M. Bauer, R.N. Hoover, A.G. Glass, D.M. Cadell, and B.B. Rush Epidemiology evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia J. Natl. Cancer Inst. 85 1993 958 964
8. F.O. Wettstein State of viral DNA and gene expression in benign vs. malignant tumors H. Pfister Papillomaviruses and human cancer 1990 CRC Press Florida 145
9. K. Seedorf, T. Oltersdorf, G. Krammer, and W. Rowekamp Identification of early proteins of the papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells EMBO J. 6 1987 139 144
10. K. Munger, W.C. Phelps, V. Bubb, P.M. Howley, and R. Schlegel The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes J. Virol. 63 1989 4417 4421
11. L. Gissmann, and M. Durst Cell transformation by human papillomaviruses H. Pfister Papillomaviruses and human cancer 1990 CRC Press Florida 145
12. M. von Knebel Doeberitz, T. Oltersdorf, E. Schwarz, and L. Gissmann Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells Cancer Res. 48 1988 3780 3786
13. S. Duensing, L.Y. Lee, A. Duensing, J. Baile, P. Siribangon, and S. Gonzalez The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division Proc. Natl. Acad. Sci. U. S. A. 97 1988 10002 10007
14. J. Cason, P.K. Kambo, J.M. Best, and D.J. McCance Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children Int. J. Cancer 50 1992 349 355
15. E. Hamsikova, J. Novak, V. Hofmannova, N. Munoz, F.X. Bosch, and S. de Sanjose Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls J. Infect. Dis. 170 1994 1424 1431
16. P.K. Jha, V. Beral, J. Peto, S. Hack, C. Hermon, and J. Deacon Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk Lancet 341 1993 1116 1118
17. I. Jochmus-Kudielka, A. Schneider, R. Braun, R. Kimmig, U. Koldovsky, and K.E. Schneweis Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer J. Natl. Cancer Inst. 81 1989 1698 1704
18. T. Onda, T. Kanda, S. Zanma, T. Yasugi, S. Watanabe, and T. Kawana Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA Int. J. Cancer 54 1989 624 628
19. R.P. Viscidi, Y. Sun, B. Tsuzaki, F.X. Bosch, N. Munoz, and K.V. Shah Serologic response in human papillomavirus-associated invasive cervical cancer Int. J. Cancer 55 1993 780 784
20. M. Nakagawa, D.P. Stites, S. Farhat, A. Judd, A.B. Moscicki, and A.J. Canchola T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia Clin. Diagn. Lab. Immunol. 3 1996 205 210
21. T. Tsukui, A. Hildesheim, M.H. Schiffman, J. Lucci III, D. Contois, and P. Lawler Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology Cancer Res. 56 1996 3967 3974
22. M.C. Feltkamp, H.L. Smits, M.P. Vierboom, R.P. Minnaar, B.M. de Jongh, and J.W. Drijfhout Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur. J. Immunol. 23 1993 2242 2249
23. M. Clerici, M. Merola, E. Ferrario, D. Trabattoni, M.L. Villa, and B. Stefanon Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection J. Natl. Cancer Inst. 89 1997 245 250
24. T.K. Park, S.N. Kim, D.H. Choi, and C.H. Lee Cell-mediated immunity in cervical intraepithelial neoplasia Asia-Oceania J. Obstet. Gynaecol. 18 1992 171 175
25. G. Strang, J.K. Hickling, G.A. McIndoe, K. Howland, D. Wilkinson, and H. Ikeda Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity J. Gen. Virol. 71 1990 423 431
26. R.W. Tindle, G.J. Fernando, J.C. Sterling, and I.H. Frazer A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes Proc. Natl. Acad. Sci. U. S. A. 88 1991 5887 5891
27. P.S. Shepherd, T.T. Tran, A.J. Rowe, J.C. Cridland, S.A. Comerford, and M.G. Chapman T cell responses to the human papillomavirus type 16 E7 protein in mice of different haplotypes J. Gen. Virol. 73 1992 1269 1274
28. H.J. Stauss, H. Davies, E. Sadovnikova, B. Chain, N. Horowitz, and C. Sinclair Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus Proc. Natl. Acad. Sci. U. S. A. 89 1992 7871 7875
29. W.M. Kast, R.M. Brandt, J.W. Drijfhout, and C.J. Melief Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2 J. Immunotherapy 14 1993 115 120
30. K.J. Sastry, P.N. Nehete, S. Venkatnarayanan, J. Morkowski, C.D. Platsoucas, and R.B. Arlinghaus Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120 Virology 188 1992 502 509
31. A.K. Sarkar, G. Tortolero-Luna, P.N. Nehete, R.B. Arlinghaus, M.F. Mitchell, and K.J. Sastry Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16 Viral Immunol. 8 1995 165 174
32. M. Nakagawa, D.P. Stites, S. Farhat, J.R. Sisler, B. Moss, and F. Kong Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia J. Infect. Dis. 175 1997 927 931
33. Kadish AS, Ho GYF, Burk RD, Wang Y, Romney SL, Ledwidge R, et al., Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 89:1285-1293.
34. T.D. De Gruijil, H.J. Bontkes, M.J. Stukart, J.M. Walboomers, A.J. Remmik, and R.H. Verheijen T cell proliferative responses against human papillomavirus type E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent infection J. Gen. Virol. 77 1996 2183 2191
35. T.D. De Gruijil, H.J. Bontkes, J.M. Walboomers, M.J. Stukart, F.S. Doekhie, and A.J. Remmik Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study Cancer Res. 58 1998 1700 1706
36. Y. Ting, and M.M. Manos Detection and typing of human papillomaviruses M. Innis D.H. Gelfand J.J. Sninsky T.J. White PCR protocols: a guide to methods and applications 1990 Academic Press New York 356 367
37. M.H. Schiffman, H.M. Bauer, A.T. Lorincz, M.M. Manos, J.C. Byrne, and A.G. Glass Comparison of Southern blot hybridization and polymerase chain reaction methods for detection of human papillomavirus DNA J. Clin. Microbiol. 29 1991 573 577
38. R.B. Merrifield Solid phase peptide synthesis J. Am. Chem. Soc. 85 1963 2149 2154
39. R.A. Houghten General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids Proc. Natl. Acad. Sci. U. S. A. 82 1985 5131 5135
40. P.N. Nehete, P.C. Johnson, S.J. Schapiro, R.B. Arlinghaus, and K.J. Sastry Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals J. Clin. Immunol. 16 1996 115 124
41. R.D. Schrier T cell recognition of HIV synthetic peptides in natural infection J. Immunol. 142 1989 1166 1176
42. O. Pontesilli HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals Clin. Exp. Immunol. 100 1995 419 424
43. P.N. Nehete A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans Viral Immunol. 11 1998 147 158
44. C.A. Ryan Examination of a vehicle for use with water soluble materials in the murine local lymph node assay Food Chem. Toxicol. 40 2002 1719 1725
45. P.N. Nehete Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic HIV-rhesus model Vaccine 20 2002 813 825
46. L.A. Koutsky Epidemiology of genital human papillomavirus infection Am. J. Med. 102 1997 3 8
47. D.S. Heller, M. Hameed, and B. Cracchiolo Presence and quantification of macrophages in squamous cell carcinoma of the cervix Int. J. Gynecol. Cancer 13 2003 67 70
48. N. Coleman, H.D. Birley, and A.M. Renton Immunological events in regressing genital warts Am. J. Clin. Pathol. 102 1994 768 774
49. M.J. Welters, A. de Jong, and S.J. van den Eeden Frequent display of human papilloma virus type 16 E6-specific memory of T-helper cells in the healthy population as witness of previous viral encounter Cancer Res. 63 2003 636 641
50. P.S. Shepherd, A.J. Rowe, and J.C. Cridland Proliferative T-cell responses to human papilloma virus type 16 L1 peptides in patients with cervical dysplasia J. Gen. Virol. 77 4 1996 593 602
51. T.D. de Gruiji, H.J. Bontkes, and J.M. Walboomers Analysis of IgG reactivity against human papilloma virus type 16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study Int. J. Cancer 68 1996 731 738
52. J. Maclean, E.P. Rybicki, and A.-L. Williamson Vaccination strategies for the prevention of cervical cancer Expert Rev. Anticancer Ther. 5 1 2005 97 107
53. E. Franco, and D.M. Harper Vaccination against human papilloma virus infection: a new paradigm in cervical cancer control Vaccine 23 2005 2388 2394
54. P.L. Stern Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination J. Clin. Virol. 32 S 2005 S72 S91
55. N.D. Christensen Emerging human papillomavirus vaccines Expert Opin. Emerg. Drugs 10 1 2005 5 19
56. I.H. Frazer, and R.W. Tindle Cell-mediated immunity to papillomaviruses Papillomavirus Rep. 3 1992 53 58
57. C. Benton, H. Shahidullah, and J.A.A. Hunter Human papillomavirus in the immunosuppressed Papillomavirus Rep. 3 1992 23 36
58. K. Iwatsuki, H. Tagami, M. Takigawa, and M. Yamada Plane warts under spontaneous regression: immunopathologic study on cellular constituents leading to the inflammatory reaction Arch. Dermatol. 122 1986 655 659
59. S.K. Tay, D. Jenkins, P. Maddox, M. Campion, and A. Singer Subpopulations of Langerhans' cells in cervical neoplasia Br. J. Obstet. Gynaecol. 94 1987 10 15
60. R.J. Apple, H.A. Erlich, W. Klitz, M.M. Manos, T.M. Becker, and C.M. Wheeler HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity Nat. Genet. 6 1994 157 162
61. K. Odunsi, G. Terry, L. Ho, J. Bell, J. Cuzick, and T.S. Ganesan Association between HLA DQB1*03 and cervical intra-epithelial neoplasia Mol. Med. 1 1995 161 171
62. M. Nakagawa, D.P. Stites, J.M. Palefsky, Z. Kneass, and A.-B. Moscicki CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses Clin. Diagn. Lab. Immunol. 6 1999 494 498
63. A.D. Santin, P.L. Hermonat, A. Ravaggi, S. Bellone, S. Pecorelli, and J.J. Roman Interleukin-10 increases Th1 cytokine production and cytotoxic potential of human papillomavirus-specific CD8+ cytotoxic T lymphocytes J. Virol. 74 2000 4729 4737
64. A. Sher, R.T. Gazzinelli, I.P. Oswald, M. Clerici, M. Kullberg, and E.J. Pearce Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection Immunol. Rev. 127 1992 183 204
65. M. Yamamura, K. Uyemura, R.J. Deans, K. Weinberg, T.H. Rea, and B.R. Bloom Defining protective responses to pathogens: cytokine profiles in leprosy lesions Science 254 1991 277 279
66. M. Clerici, and G.M. Shearer The Th1-Th2 hypothesis of HIV infection: new insights Immunol. Today 15 1994 575 581
67. W.M.J. Schoell, R. Mirhashemi, B. Liu, M.F. Janicek, E.R. Podack, and M.A. Penalver Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer Gynecol. Oncol. 74 1999 448 455
68. A.D. Santin, P.L. Hermonat, A. Ravaggi, M. Chiriva-Internati, D. Zhan, and S. Pecorelli Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-postivie cervical cancer J. Virol. 73 1999 5402 5410